These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 19218991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
    Cheng KC, Wu WC, Chen KJ.
    Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Tao Y, Hou J, Jiang YR, Li XX, Jonas JB.
    Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Cekiç O, Cakır M, Yazıcı AT, Alagöz N, Bozkurt E, Faruk Yılmaz O.
    Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
    Alshareef RA, Garg SJ, Hsu J, Vander J, Park C, Spirn MJ.
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S, Rush R, Natarajan S, Gillies M.
    Clin Exp Ophthalmol; 2011 Aug; 39(7):673-81. PubMed ID: 22452685
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
    Patel PJ, Zaheer I, Karia N.
    Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
    Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R.
    Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
    Gokce G, Sobaci G, Durukan AH, Erdurman FC.
    Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
    Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA.
    Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y, Arimura N, Shimura M, Sakamoto T.
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
    Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN.
    Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
    [Abstract] [Full Text] [Related]

  • 17. [Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide].
    Le Moigne O, Duncombe A, Portmann A, Muraine M, Genevois O.
    J Fr Ophtalmol; 2012 Nov; 35(9):700-4. PubMed ID: 22925843
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion.
    Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR, Ai E.
    Retina; 2006 Oct; 26(8):896-901. PubMed ID: 17031289
    [Abstract] [Full Text] [Related]

  • 19. Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.
    Kwon SI, Kim YW, Bang YW, Lee JY, Park IW.
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):5-9. PubMed ID: 23237542
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion.
    Krepler K, Ergun E, Sacu S, Richter-Müksch S, Wagner J, Stur M, Wedrich A.
    Acta Ophthalmol Scand; 2005 Feb; 83(1):71-5. PubMed ID: 15715561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.